http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-201300207-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 |
| filingDate | 2011-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EA-201300207-A1 |
| titleOfInvention | DERIVATIVE INSULIN, OWNED SUGAR-DECREASING ACTIVITY AT ORAL APPLICATION, METHOD OF ITS OBTAINING AND DRUG FORM ON ITS BASIS |
| abstract | The invention relates to pharmacy and medicine, in particular to orally administered compositions of a biologically active substance, in particular supramolecular insulin oligopeptide ensembles for the treatment of diabetes mellitus, its complications. This system allows for 24 hours with a single oral administration to keep the blood glucose level at the physiological level (super-effect), and the system components become resistant to the action of enzymes and are small in size, able to be easily absorbed from the intestine. SUMMARY OF THE INVENTION A supramolecular composition — an ensemble of acylated oligopeptides — products of enzymatic hydrolysis of insulin — is used as the main active agents. The composition can be produced by industry in sufficient quantities, taking into account the availability of all components of the composition. |
| priorityDate | 2011-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 97.